Ireland’s Minister for Health has published a consultation paper on overhauling the nation’s approach to biosimilar medicines. The paper indicates that the Irish government is developing a National Biosimilar Medicines Policy “to promote the rational use of biosimilar medicines and to create a sustainable environment for biological medicines in Ireland.”
Ireland’s Minister for Health has published a consultation paper on overhauling the nation’s approach to biosimilar medicines. The paper indicates that the Irish government is developing a National Biosimilar Medicines Policy “to promote the rational use of biosimilar medicines and to create a sustainable environment for biological medicines in Ireland.”
The consultation paper highlights the fact that only 11 biosimilars are currently reimbursable by the state’s healthcare system, while over €200 million (approximately $235 million) is spent each year on biologic drugs that already have approved biosimilars or that will have available biosimilars by 2018.
Currently, Ireland’s Health Products Regulatory Authority supports physician-led switching of biologics and biosimilars, but stresses that any change in prescribing should be made in consultation with the patient. However, the health authority discourages repeated switches and prohibits automatic substitution with biosimilars at the pharmacy level. Looking forward, the paper indicates that Ireland should consider the following policies and how they have affected biosimilar uptake in the European Union (EU) in order to inform its own approach to the drugs:
Prescribing
Education
Incentives and Disincentives
Tendering and Pricing
Preventing Inappropriate Business Practices
Publication of the consultation paper follows a Department of Public Expenditure report, published in May, that urged the Irish government to make substantial changes to its policies in order to rein in drug spending. The paper explained that the Irish government spends €2 billion per year (approximately $2.36 billion), or 15% of its total healthcare expenditure, on drugs. That number is only expected to grow as new, high-cost drugs continue to dominate the healthcare marketplace; the paper cited an estimated 3% annual growth in drug spending until 2020.
The report also noted that Ireland has one of the lowest biosimilar adoption levels in Europe, across both EU- and non-EU states. With only a 15% uptake for biosimilar granulocyte colony-stimulating factor, Ireland was second only to Belgium in terms of the smallest market share for biosimilars.
The Irish Department of Health is holding a public comment period on the consultation paper through September 22, 2017.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
BioRationality: Commemorating the 15th Anniversary of the BPCIA
April 8th 2025Affirming that analytical characterization is often sufficient for biosimilar approval, minimizing unnecessary clinical testing, and enhancing FDA-led education to counter stakeholder misconceptions are key recommendations put forth in this opinion piece by Sarfaraz K. Niazi, PhD.